larrygobfiend
Player Valuation: £40m
China’s treatment of the Uighur Muslims tells you everything you need to know about their government and what they’re capable of.
Interesting that it's assumed corbyn and Labour, who would be disastrous as they would do things so differently it would wreck the economy, wouldn't do anything different/better in the face of this crisis...
He is a Nobel prize winner in medical field? Did he mention his scientific opinion of the virus?
Don't forget Chinas treatment of their own in Tiananmen Square in 1989 which told you what the CCP are capable of.China’s treatment of the Uighur Muslims tells you everything you need to know about their government and what they’re capable of.
Seems every bugger and their dog was travelling in Italy & Asia bringing this thing back with them in February.
Whilst we are playing the blame game- has anyone mentioned middle class jet setters with more money than sense?
Seems every bugger and their dog was travelling in Italy & Asia bringing this thing back with them in February.
If more people went to Pontins or Blackpool instead we would all be out in a beer garden right now instead of being stuck in with hair growing over our ears.
'Koff.
I'm working class.
I haven’t had a go at Germany, all I‘ve ever said is that we shouldn’t use their numbers for comparisons because I believe they categorise them differently. Indeed if our numbers are over 25k then their 4K is definitely measured or categorised differently somehow. China is another issue and I do blame them for this pandemic.
In terms of seeing how things are progressing I stand by trends. But trends need to see numbers that are consistently and accurately recorded. The U.K. is measuring numbers provided by hospitals, because they are the systems that are connected or can provide quick reliable data. There are over 20,000 care homes, whose systems are not interconnected and would be incapable of providing regular and stable daily numbers at a precise point in time. Therefore providing we concentrate on the subset which we know is reliable and accurate we can see the trend. That is the point I was making...
Lockdown till july it seems then with the furlugh sceme thing...
Gunna take some getting over this, economy wise and mental health wise
Cheers mate, it's a scandalous situation. All these front line NHS staff and many others have been seriously let down.We are struggling for gowns across the water to, we haven’t got as bad as that and are using some aprons in low risk situations, but I’d have no problem makeshifting a bin bag, rather then go in with nothing or disinfect an infected gown - no chance. I’d be taking a picture of my big bag gown as well and let it go viral. You’d soon see gowns turn up smart.
Best wishes to your partner mate, hope she’s safe and well.
What a surprise, media drives the public to demand a silver bullet, and the government cocks it up.We paid upfront without testing them, it's our fault.
![]()
U.K. Paid $20 Million for New Coronavirus Tests. They Didn’t Work. (Published 2020)
Facing a global scramble for materials, British officials bought millions of unproven kits from China in a gamble that became an embarrassment.www.nytimes.com
U.K. Paid $20 Million for New Coronavirus Tests. They Didn’t Work.
Facing a global scramble for materials, British officials bought millions of unproven kits from China in a gamble that became an embarrassment.
![]()
Parliament in London. Britain is aiming to conduct 100,000 coronavirus tests a day by May, but as of this week was still doing less than 20,000 a day.
LONDON — The two Chinese companies were offering a risky proposition: two million home test kits said to detect antibodies for the coronavirus for at least $20 million, take it or leave it.
The asking price was high, the technology was unproven and the money had to be paid upfront. And the buyer would be required to pick up the crate loads of test kits from a facility in China.
Yet British officials took the deal, according to a senior civil servant involved, then confidently promised tests would be available at pharmacies in as little as two weeks. “As simple as a pregnancy test,” gushed Prime Minister Boris Johnson. “It has the potential to be a total game changer.”
There was one problem, however. The tests did not work.
Found to be insufficiently accurate by a laboratory at Oxford University, half a million of the tests are now gathering dust in storage. Another 1.5 million bought at a similar price from other sources have also gone unused. The fiasco has left embarrassed British officials scrambling to get back at least some of the money.
“They might perhaps have slightly jumped the gun,” said Prof. Peter Openshaw of Imperial College London, a member of the government’s New and Emerging Respiratory Virus Threats Advisory Group. “There is a huge pressure on politicians to come out and say things that are positive.”
A spokesperson from the Department of Health and Social Care said that the government had ordered the smallest number of tests allowed by the sellers and that it would try to recover the money, without specifying how.
The ill-starred purchases are in some ways a parable of the risks in the escalating scrum among competing governments racing for an edge in the fight against the pandemic.
The still-emerging tests for antibodies formed in response to the virus are the next stage in the battle. By enabling public health officials to assess where the disease has spread and who might have some immunity, widespread use of the tests is seen as a critical step in determining how and when to lift the lockdowns currently paralyzing societies and economies in much of the world.
“You can’t lift the lockdown as long as you are not testing massively,” said Nicolas Locker, a professor of virology at the University of Surrey. “As long as the government is not testing in the community, we are going to be on lockdown.”
The gamble on the Chinese antibody tests, though, is also a barometer of the desperation British officials felt as public pressure has mounted over their slow response to the virus. One prominent expert, Jeremy Farrar, the head of the Wellcome Trust, a British nonprofit that is a major funder of medical research, recently warned that “the U.K. is likely to be certainly one of the worst, if not the worst affected, country in Europe.”
Long before the development of an antibody test, Germany, for example, the continent’s leader in containing the virus, began conducting as many as 50,000 diagnostic tests a day to help trace and isolate cases. That rate is now nearly 120,000 a day.
As of Wednesday, Britain was still conducting less than 20,000 diagnostic tests a day. Having missed a previous target of 25,000 diagnostic tests a day by the middle of April, officials are now promising to reach 100,000 a day by the end of the month and as many as 250,000 a day soon after that.
British officials have said that they started out behind because they lack major private testing companies of the sort found in Germany and the United States, which are capable of manufacturing and performing tens of thousands of diagnostic tests.
But by the time Britain began pushing in earnest to expand its capacity, it was also trailing behind most of Europe in the competition to buy up the limited supply of compounds, tubes and even swabs needed for diagnostic tests to determine a current infection with the virus.
So when the Chinese offers of antibody tests arrived, the officials knew that almost every government in the world was hunting for them, too. Nationalists like President Trump were pressuring domestic suppliers not to sell outside their borders. Oil-rich Persian Gulf princes were bidding up prices.
Medical companies in China, where the virus first emerged, seemed to hold all the cards, typically demanding yes-or-no decisions from buyers with full payment upfront in as little as 24 hours.
The two Chinese companies offering the antibody tests, AllTest Biotech and Wondfo Biotech, both said their products met the health, safety and environmental standards set by the European Union. Public health officials reviewed the specifications on paper while the British Foreign Ministry hurriedly dispatched diplomats in China to ensure the companies existed and to examine their products.
Representatives of both AllTest and Wondfo declined to discuss prices.
Within days of the deal, enthusiastic health officials back in London were promising that the new tests would vault Britain into the vanguard of international efforts to combat the virus.
Appearing on March 25 before a parliamentary committee, Sharon Peacock, a professor of public health and microbiology at Cambridge University who is the senior public health official overseeing infectious diseases, testified that the tests would require only a pin prick in the privacy of one’s home and would soon be available at minimal cost from either local pharmacies or Amazon.
Sign up to receive an email when we publish a new story about the coronavirus outbreak.
“Testing the test is a small matter,” Prof. Peacock assured lawmakers. “I anticipate that it would be done by the end of this week.”
After quietly admitting last week that the testing had in fact proven unsuccessful, health officials are now defending the purchase as prudent planning and valuable experience.
It was to be expected, Prof. Chris Whitty, Britain’s chief medical officer, said in a news conference. “It would be very surprising if first out of the gate we got to the best outcome that we could for this kind of test,” he said. “It made a lot of sense to get started early.”
But Greg Clark, the chairman of a parliamentary committee examining the coronavirus response, said the government’s promises appeared unrealistic.
“There is no country in the world that is able to operate in massive scale antibody tests yet,” he said in an interview.
“I think it’s now clear,” he added, “that we should have moved earlier and more expansively to make use of all of the testing facilities that we could have.”
After British complaints about the test kits surfaced, both Chinese companies blamed British officials and politicians for misunderstanding or exaggerating the utility of the tests. Wondfo told Global Times, a Chinese newspaper, that its product was intended only as a supplement for patients who had already tested positive for the virus.
AllTest said in a statement on its website that the tests were “only used by professionals,” not by patients at home.
Doctors say the government’s descriptions of the antibody tests could also be misleading.
By comparing the antibody tests to pregnancy tests, officials seemed to be suggesting the antibody tests would determine whether a patient was currently infected. But a discernible level of antibodies may not appear in the blood until as long as 20 days after infection — meaning a person with the virus would test negative until then.
The British military laboratory at Porton Down is also working on an antibody test, but primarily to help public health officials assess the course of the pandemic by surveying samples of the population, not to inform individual patients. The government is hoping to repurpose some of the stored Chinese-made kits for this sort of population-level testing.
Do-it-yourself pinprick tests like the ones the British government ordered from China are far more complicated and much further off than such laboratory tests, researchers say. It is not yet certain what degree of immunity recovery from a past infection may confer, either.
Rapid antibody tests “have limited utility” for patients, the World Health Organization warned in an April 8 statement, telling doctors that such tests remained unfit for clinical purposes until they were proved to be accurate and effective.
British officials, though, were eager for a breakthrough.
Even in late March, as the pandemic overwhelmed hospitals in Italy and Iran, British officials brushed off the advice of the World Health Organization to expand diagnostic testing as quickly as possible.
By the time Britain began pushing in earnest to expand its testing, every country in the world was competing for the same materials.
To make up the shortfall, academic research laboratories have sought to convert themselves into small-scale clinical testing facilities, typically focusing on the needs of local hospitals.
“If it comes around from the government, all well and good,” said Ravindra Gupta, professor of clinical microbiology at Cambridge University’s Department of Medicine, “but we have to prepare for nothing to come. It would be crazy to wait.”
Cancer Research UK, a nonprofit organization, is converting its research laboratories to conduct as many as 2,000 tests a day. But its capacity has been limited to a few hundred because of difficulty and delays in obtaining scarce materials, said Prof. Charles Swanton, its chief clinical officer.
Advertisement
Even the swabs used to obtain samples had turned out to be scarce, he said, and his laboratory ultimately agreed to pay a Chinese supplier as much as $6 a swab — about 100 times the typical cost. “It took about 10 days to get them,” Professor Swanton added.
The British division of the drug giant AstraZeneca began setting up a testing facility last month for its own essential workers, said Mene Pangalos, the executive overseeing the effort. But at the request of the British government, AstraZeneca and its rival drug company GlaxoSmithKline have teamed up to repurpose a laboratory at Cambridge University to carry out as many as 30,000 diagnostic tests a day by the beginning of May.
AstraZeneca hopes to develop a laboratory test for antibodies, too, Mr. Pangalos said. But that will take until at least the middle of next month, and a home-based test, such as the British government tried to order, would take much longer, he added.
“Everyone is overpromising at the moment,” he said. “I don’t want to overpromise.”
Join the Everton conversation today.
Fewer ads, full access, completely free.